SER-109
SERES-012
Phase 3 mab completed
Quick answer
SER-109 for Clostridium Difficile Infection is a Phase 3 program (mab) at Seres Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Seres Therapeutics
- Indication
- Clostridium Difficile Infection
- Phase
- Phase 3
- Modality
- mab
- Status
- completed